CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Amazon Explores AI Content Marketplace With Media Publishers 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
REGULATED INFORMATION
GHENT, Belgium, 15 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 179,781 common shares have been issued by the Company in exchange for €782,096.92 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has a share capital of €140,671,002.58 represented by a total number of 75,253,667 shares, conferring a total number of 75,253,667 voting rights.
The current total number of outstanding rights (warrants) to subscribe for not yet issued securities conferring voting rights is 2,747,725, entitling their holders to subscribe for a total number of 2,747,725 new shares, conferring a total number of 2,747,725 voting rights.
The current total number of outstanding convertible bonds is 983, which, on the basis of the current conversion price of €12.6631, are convertible into 7,761,768 new shares, conferring a total number of 7,761,768 voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: [email protected]
Joele Frank, Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f4b2bef2-a87b-48d2-90d4-c7bce1d7d2f1
